Cargando…

One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema

PURPOSE: To assess the 12 month outcomes of intravitreal faricimab (IVF) in treatment-resistant diabetic macular edema (DME) recalcitrant to intravitreal aflibercept (IVA). METHODS: This study was undertaken as a retrospective interventional case series of DME subjects receiving care at a single pri...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rush, Ryan B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440101/ https://www.ncbi.nlm.nih.gov/pubmed/37605765 http://dx.doi.org/10.2147/OPTH.S424314

Ejemplares similares

Faricimab for Treatment-Resistant Diabetic Macular Edema
por: Rush, Ryan B, et al.
Publicado: (2022)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
por: Abouhussein, Mahmoud Alaa, et al.
Publicado: (2021)

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
por: Tamiya, Ryosuke, et al.
Publicado: (2023)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023)

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema
por: Kusuhara, Sentaro, et al.
Publicado: (2023)

Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema
por: Takamura, Yoshihiro, et al.
Publicado: (2023)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2021)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021)

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol
por: Kaiho, Tomomi, et al.
Publicado: (2017)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)

The role of aflibercept in the management of diabetic macular edema
por: Chang, Andrew A, et al.
Publicado: (2015)

The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017)

YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
por: Eter, Nicole, et al.
Publicado: (2021)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2022)

Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol
por: Hayashi, Yuko, et al.
Publicado: (2021)

The efficacy and safety of aflibercept and conbercept in diabetic macular edema
por: Cai, Siwei, et al.
Publicado: (2018)

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo, Rafael, et al.
Publicado: (2018)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
por: Lin, Tai-Chi, et al.
Publicado: (2021)

Contrast Sensitivity Changes in Center Involving Diabetic Macular Edema Treated with Aflibercept
por: Nixon, Donald R, et al.
Publicado: (2021)

Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
por: Montes Rodríguez, Paula, et al.
Publicado: (2022)

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
por: Hirano, Takao, et al.
Publicado: (2021)

Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs
por: Ramsey, David J, et al.
Publicado: (2021)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DAM Study)
por: Koushan, Keyvan, et al.
Publicado: (2022)

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population
por: Braimah, Imoro Zeba, et al.
Publicado: (2022)

Changes in metamorphopsia following intravitreal aflibercept injection for diabetic macular edema
por: Murakami, Tomoya, et al.
Publicado: (2022)

Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study
por: Akbas, Yusuf Berk, et al.
Publicado: (2023)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2clak39bpfpnq43fn9ekapuehg